(CTKB) Cytek Biosciences - Ratings and Ratios
Aurora,Northern-Lights,Sorters,Imagers,Reagents
CTKB EPS (Earnings per Share)
CTKB Revenue
Description: CTKB Cytek Biosciences October 25, 2025
Cytek Biosciences, Inc. (NASDAQ:CTKB) develops and sells advanced cell-analysis instrumentation and reagents for biomedical research, drug discovery, and clinical applications. Its flagship platforms-Aurora and Northern Lights-use full-spectrum flow cytometry to enable high-dimensional phenotyping, while complementary products such as the Amnis ImageStream, Guava Muse/EasyCyte analyzers, and Orion reagent-cocktail systems broaden the addressable market across both research and clinical labs.
The company’s ecosystem includes automated sample-handling hardware (micro-sampling and loader systems), the SpectroFlo software suite for end-to-end data workflow, and a portfolio of cFluor-conjugated antibodies that are sold as consumables. Distribution is a mix of direct sales in North America, Europe, China, and APAC, supplemented by regional distributors in Latin America and the Middle East.
Key market metrics that shape Cytek’s outlook: (1) the global flow cytometry market is projected to grow at a ~8% CAGR through 2030, driven by expanding immuno-oncology pipelines and the rise of single-cell omics; (2) CTKB reported FY 2024 revenue of roughly $84 million, a 22% year-over-year increase, with cash and equivalents of $55 million, providing runway for R&D and international expansion; (3) the company’s R&D spend has risen to ~15% of revenue, reflecting its focus on full-spectrum and imaging flow technologies that differentiate it from legacy vendors such as BD and Thermo Fisher.
For a deeper, data-driven assessment of CTKB’s valuation and risk profile, you might find the analytical tools on ValueRay useful.
CTKB Stock Overview
| Market Cap in USD | 496m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2021-07-23 |
CTKB Stock Ratings
| Growth Rating | -79.0% |
| Fundamental | 40.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -37.3% |
| Analyst Rating | 3.33 of 5 |
CTKB Dividends
Currently no dividends paidCTKB Growth Ratios
| Growth Correlation 3m | -17.5% |
| Growth Correlation 12m | -64.2% |
| Growth Correlation 5y | -93.6% |
| CAGR 5y | -35.69% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.43 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.66 |
| Sharpe Ratio 12m | -0.64 |
| Alpha | -46.19 |
| Beta | 1.317 |
| Volatility | 63.63% |
| Current Volume | 1253.7k |
| Average Volume 20d | 619.9k |
| Stop Loss | 3.6 (-7.9%) |
| Signal | 0.48 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-6.40m TTM) > 0 and > 6% of Revenue (6% = 11.8m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA 0.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 157.9% (prev 167.8%; Δ -9.87pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 15.2m > Net Income -6.40m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (126.9m) change vs 12m ago -3.43% (target <= -2.0% for YES) |
| Gross Margin 54.42% (prev 54.97%; Δ -0.55pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 40.13% (prev 40.87%; Δ -0.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.17 (EBITDA TTM -8.51m / Interest Expense TTM 1.52m) >= 6 (WARN >= 3) |
Altman Z'' 3.21
| (A) 0.63 = (Total Current Assets 382.8m - Total Current Liabilities 73.3m) / Total Assets 493.3m |
| (B) -0.11 = Retained Earnings (Balance) -52.2m / Total Assets 493.3m |
| (C) -0.01 = EBIT TTM -6.32m / Avg Total Assets 488.5m |
| (D) -0.45 = Book Value of Equity -52.1m / Total Liabilities 115.8m |
| Total Rating: 3.21 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 40.06
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield 4.46% = 2.23 |
| 3. FCF Margin 5.64% = 1.41 |
| 4. Debt/Equity 0.04 = 2.50 |
| 5. Debt/Ebitda 7.21 = -2.50 |
| 6. ROIC - WACC (= -11.97)% = -12.50 |
| 7. RoE -1.66% = -0.28 |
| 8. Rev. Trend 26.66% = 2.00 |
| 9. EPS Trend 4.01% = 0.20 |
What is the price of CTKB shares?
Over the past week, the price has changed by -6.90%, over one month by -2.74%, over three months by +1.82% and over the past year by -24.81%.
Is Cytek Biosciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CTKB is around 2.55 USD . This means that CTKB is currently overvalued and has a potential downside of -34.78%.
Is CTKB a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 3
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the CTKB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.1 | 31.2% |
| Analysts Target Price | 5.1 | 31.2% |
| ValueRay Target Price | 2.9 | -26.1% |
CTKB Fundamental Data Overview November 04, 2025
P/E Forward = 370.3704
P/S = 2.531
P/B = 1.2299
Beta = 1.317
Revenue TTM = 196.0m USD
EBIT TTM = -6.32m USD
EBITDA TTM = -8.51m USD
Long Term Debt = 791.0k USD (from longTermDebt, last quarter)
Short Term Debt = 5.44m USD (from shortLongTermDebt, last quarter)
Debt = 14.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -61.4m USD (from netDebt column, last quarter)
Enterprise Value = 248.3m USD (496.2m + Debt 14.1m - CCE 262.0m)
Interest Coverage Ratio = -4.17 (Ebit TTM -6.32m / Interest Expense TTM 1.52m)
FCF Yield = 4.46% (FCF TTM 11.1m / Enterprise Value 248.3m)
FCF Margin = 5.64% (FCF TTM 11.1m / Revenue TTM 196.0m)
Net Margin = -3.27% (Net Income TTM -6.40m / Revenue TTM 196.0m)
Gross Margin = 54.42% ((Revenue TTM 196.0m - Cost of Revenue TTM 89.4m) / Revenue TTM)
Gross Margin QoQ = 52.34% (prev 48.62%)
Tobins Q-Ratio = 0.50 (Enterprise Value 248.3m / Total Assets 493.3m)
Interest Expense / Debt = 2.93% (Interest Expense 414.0k / Debt 14.1m)
Taxrate = 17.59% (-1.19m / -6.78m)
NOPAT = -5.21m (EBIT -6.32m * (1 - 17.59%)) [loss with tax shield]
Current Ratio = 5.22 (Total Current Assets 382.8m / Total Current Liabilities 73.3m)
Debt / Equity = 0.04 (Debt 14.1m / totalStockholderEquity, last quarter 377.6m)
Debt / EBITDA = 7.21 (negative EBITDA) (Net Debt -61.4m / EBITDA -8.51m)
Debt / FCF = -5.55 (Net Debt -61.4m / FCF TTM 11.1m)
Total Stockholder Equity = 384.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.30% (Net Income -6.40m / Total Assets 493.3m)
RoE = -1.66% (Net Income TTM -6.40m / Total Stockholder Equity 384.6m)
RoCE = -1.64% (EBIT -6.32m / Capital Employed (Equity 384.6m + L.T.Debt 791.0k))
RoIC = -1.34% (negative operating profit) (NOPAT -5.21m / Invested Capital 389.6m)
WACC = 10.64% (E(496.2m)/V(510.3m) * Re(10.87%) + D(14.1m)/V(510.3m) * Rd(2.93%) * (1-Tc(0.18)))
Discount Rate = 10.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.46%
[DCF Debug] Terminal Value 58.88% ; FCFE base≈10.9m ; Y1≈7.16m ; Y5≈3.27m
Fair Price DCF = 0.34 (DCF Value 43.4m / Shares Outstanding 127.2m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 4.01 | EPS CAGR: -17.72% | SUE: 0.14 | # QB: 0
Revenue Correlation: 26.66 | Revenue CAGR: 4.43% | SUE: -0.28 | # QB: 0
Additional Sources for CTKB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle